These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 20830775)

  • 1. Thyroid and hepatic function after high-dose 131 I-metaiodobenzylguanidine (131 I-MIBG) therapy for neuroblastoma.
    Quach A; Ji L; Mishra V; Sznewajs A; Veatch J; Huberty J; Franc B; Sposto R; Groshen S; Wei D; Fitzgerald P; Maris JM; Yanik G; Hawkins RA; Villablanca JG; Matthay KK
    Pediatr Blood Cancer; 2011 Feb; 56(2):191-201. PubMed ID: 20830775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term follow-up of the thyroid gland after treatment with 131I-Metaiodobenzylguanidine in children with neuroblastoma: importance of continuous surveillance.
    Clement SC; van Eck-Smit BL; van Trotsenburg AS; Kremer LC; Tytgat GA; van Santen HM
    Pediatr Blood Cancer; 2013 Nov; 60(11):1833-8. PubMed ID: 23832530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High incidence of thyroid dysfunction despite prophylaxis with potassium iodide during (131)I-meta-iodobenzylguanidine treatment in children with neuroblastoma.
    van Santen HM; de Kraker J; van Eck BL; de Vijlder JJ; Vulsma T
    Cancer; 2002 Apr; 94(7):2081-9. PubMed ID: 11932913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary hypothyroidism as a consequence of 131-I-metaiodobenzylguanidine treatment for children with neuroblastoma.
    Picco P; Garaventa A; Claudiani F; Gattorno M; De Bernardi B; Borrone C
    Cancer; 1995 Nov; 76(9):1662-4. PubMed ID: 8635072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved radiation protection of the thyroid gland with thyroxine, methimazole, and potassium iodide during diagnostic and therapeutic use of radiolabeled metaiodobenzylguanidine in children with neuroblastoma.
    van Santen HM; de Kraker J; van Eck BL; de Vijlder JJ; Vulsma T
    Cancer; 2003 Jul; 98(2):389-96. PubMed ID: 12872361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differentiated thyroid carcinoma after 131I-MIBG treatment for neuroblastoma during childhood: description of the first two cases.
    van Santen HM; Tytgat GA; van de Wetering MD; van Eck-Smit BL; Hopman SM; van der Steeg AF; Nieveen van Dijkum EJ; van Trotsenburg AS
    Thyroid; 2012 Jun; 22(6):643-6. PubMed ID: 22524499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Thyroid dysfunction due to 131I-metaiodobenzylguanidine in patients with neuroblastoma].
    Garrido Magaña E; Silva Estrada JA; Nishimura Meguro E; Rivera Hernández AJ; Zurita Cruz JN
    Rev Chil Pediatr; 2020 Jun; 91(3):379-384. PubMed ID: 32730518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thyroid function after diagnostic
    Clement SC; Tytgat GAM; van Trotsenburg ASP; Kremer LCM; van Santen HM
    Ann Nucl Med; 2022 Jun; 36(6):579-585. PubMed ID: 35499668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thyroidal uptake and radiation dose after repetitive I-131-MIBG treatments: influence of potassium iodide for thyroid blocking.
    Brans B; Monsieurs M; Laureys G; Kaufman JM; Thierens H; Dierckx RA
    Med Pediatr Oncol; 2002 Jan; 38(1):41-6. PubMed ID: 11835235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term efficacy of current thyroid prophylaxis and future perspectives on thyroid protection during 131I-metaiodobenzylguanidine treatment in children with neuroblastoma.
    Clement SC; van Rijn RR; van Eck-Smit BL; van Trotsenburg AS; Caron HN; Tytgat GA; van Santen HM
    Eur J Nucl Med Mol Imaging; 2015 Apr; 42(5):706-15. PubMed ID: 25512056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response, survival, and toxicity after iodine-131-metaiodobenzylguanidine therapy for neuroblastoma in preadolescents, adolescents, and adults.
    Polishchuk AL; Dubois SG; Haas-Kogan D; Hawkins R; Matthay KK
    Cancer; 2011 Sep; 117(18):4286-93. PubMed ID: 21387264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different outcomes for relapsed versus refractory neuroblastoma after therapy with (131)I-metaiodobenzylguanidine ((131)I-MIBG).
    Zhou MJ; Doral MY; DuBois SG; Villablanca JG; Yanik GA; Matthay KK
    Eur J Cancer; 2015 Nov; 51(16):2465-72. PubMed ID: 26254811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of tandem 131I-metaiodobenzylguanidine infusions in relapsed/refractory neuroblastoma.
    Johnson K; McGlynn B; Saggio J; Baniewicz D; Zhuang H; Maris JM; Mosse YP
    Pediatr Blood Cancer; 2011 Dec; 57(7):1124-9. PubMed ID: 21495159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Whole-Body Radiation Dose on Response and Toxicity in Patients With Neuroblastoma After Therapy With 131 I-Metaiodobenzylguanidine (MIBG).
    Trieu M; DuBois SG; Pon E; Nardo L; Hawkins RA; Marachelian A; Twist CJ; Park JR; Matthay KK
    Pediatr Blood Cancer; 2016 Mar; 63(3):436-42. PubMed ID: 26506090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with (131)I-metaiodobenzylguanidine.
    Huibregtse KE; Vo KT; DuBois SG; Fetzko S; Neuhaus J; Batra V; Maris JM; Weiss B; Marachelian A; Yanik GA; Matthay KK
    Eur J Cancer; 2016 Oct; 66():144-52. PubMed ID: 27573428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial.
    Matthay KK; Weiss B; Villablanca JG; Maris JM; Yanik GA; Dubois SG; Stubbs J; Groshen S; Tsao-Wei D; Hawkins R; Jackson H; Goodarzian F; Daldrup-Link H; Panigrahy A; Towbin A; Shimada H; Barrett J; Lafrance N; Babich J
    J Nucl Med; 2012 Jul; 53(7):1155-63. PubMed ID: 22700000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of
    Maric I; Weber M; Prochnow A; Schmitz J; Unger N; Schaarschmidt BM; Poeppel TD; Rischpler C; Bockisch A; Herrmann K; Jentzen W; Fendler WP
    J Nucl Med; 2023 Jun; 64(6):885-891. PubMed ID: 36732054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Iodine-131--metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I study.
    Matthay KK; Quach A; Huberty J; Franc BL; Hawkins RA; Jackson H; Groshen S; Shusterman S; Yanik G; Veatch J; Brophy P; Villablanca JG; Maris JM
    J Clin Oncol; 2009 Mar; 27(7):1020-5. PubMed ID: 19171714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma.
    Matthay KK; DeSantes K; Hasegawa B; Huberty J; Hattner RS; Ablin A; Reynolds CP; Seeger RC; Weinberg VK; Price D
    J Clin Oncol; 1998 Jan; 16(1):229-36. PubMed ID: 9440747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted radiotherapy with submyeloablative doses of 131I-MIBG is effective for disease palliation in highly refractory neuroblastoma.
    Kang TI; Brophy P; Hickeson M; Heyman S; Evans AE; Charron M; Maris JM
    J Pediatr Hematol Oncol; 2003 Oct; 25(10):769-73. PubMed ID: 14528098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.